- 1Johnson & Johnson Q3 2026 (October 13): sales $25.40 billion (+6.0% operational), adjusted EPS $2.59 vs ~$2.53 consensus, FY2026 guidance raised to ~$101.2 billion in sales and $11.10 adjusted EPS at the midpoint — and the stock fell 5.7% on the day.
- 2The Triple-Overhang Test passed on both prints: in Q3 seven growth drugs added about $2.3 billion of sales year over year while Stelara and Imbruvica lost about $1.0 billion (SWOTPal calculation from J&J's sales-by-product exhibit).
- 3Talc changed state. After a July 22 court order on causation, J&J proposed a $5.5 billion resolution of about 76,000 ovarian claims on July 27, needing 95% participation, and booked a $5.52 billion charge in Q3.
- 4The biggest 2026 earnings hit was not one of the three overhangs: J&J cut its adjusted EPS guide by $0.64 on July 29 for the Firefly and Sail deals and flagged about $1.36 of 2027 dilution — the fourth overhang, the one you buy.
- 5What to watch: talc participation against the 95% threshold, MedTech growth back above ~4% operational, and the size of the 2027 deal dilution when J&J guides in January.
Strengths
- New drugs added ~$2.3B in Q3 vs ~$1.0B lost (our calc)
- Tremfya $2.40B in Q3 (+68%), Darzalex $4.24B (+15%)
- Dividend King: 64 straight annual raises; AAA rating
- FY2026 sales guide raised twice, now ~$101.2B
Weaknesses
- $5.52B talc charge took Q3 GAAP EPS to $0.09
- MedTech slowed to +2.5% in Q3 from +4.5% in Q2
- Firefly/Sail deals cut 2026 EPS guide by $0.64
- Stock fell on both 2026 print days (-2.7%, -5.7%)
Opportunities
- Talc: $5.5B proposal for ~76,000 ovarian claims
- Orthopaedics separation targeted for mid-2027
- Tecvayli +77%, Rybrevant/Lazcluze +62% in Q3
- Intra-Cellular portfolio: $5B+ potential peak sales
Threats
- Talc deal needs 95% participation to hold
- ~$1.36 of 2027 EPS dilution flagged from new deals
- IRA: Erleada on the 2028 negotiation list
- Imbruvica -19% in Q3 (US -38%) under IRA price
Johnson & Johnson is one of only two U.S. companies with a AAA credit rating higher than the U.S. government's own, a Dividend King that has raised its payout for 64 straight years, and a $94 billion healthcare empire spanning cancer drugs and heart pumps. It is also a company fighting a three-front war. This SWOT analysis was published on July 10, 2026, five days before the Q2 print. It examines how a fortress balance sheet is being tested by three simultaneous drags and introduces the single diagnostic that matters more than any headline EPS beat. It has since been graded against the Q2 (July 15) and Q3 (October 13) prints in the next section.
The Q1 2026 print set the stage: $24.06 billion in revenue (up 9.9% year-over-year) and adjusted EPS of $2.70 that beat the $2.68 consensus. The GAAP net income line of $5.24 billion looked down 52% — but only because the year-earlier quarter booked a large one-time gain, an accounting base effect rather than a real decline. The operating business grew; the question is whether it can keep growing fast enough.
Graded on Q2 and Q3 2026: The Test Passed, the Stock Fell Twice
This page asked one question before the July print: does J&J's new-product growth outrun Stelara erosion, talc litigation and IRA price cuts combined? J&J has now reported twice. Figures below are from the Q2 (July 15) and Q3 (October 13) releases and sales-by-product exhibits filed with the SEC. Consensus figures come from news coverage and stock moves are daily closes.
| Q2 2026 (Jul 15) | Q3 2026 (Oct 13) | |
|---|---|---|
| Sales | $25.31B (+6.6%; +5.6% operational) | $25.40B (+5.9%; +6.0% operational) |
| Adjusted EPS | $2.90 vs ~$2.85 consensus | $2.59 vs ~$2.53 consensus |
| Innovative Medicine | $16.38B (+7.8%) | $16.76B (+7.7%) |
| MedTech | $8.93B (+4.5%) | $8.64B (+2.5%) |
| Stelara | $740M (−55%) | $716M (−54%) |
| FY2026 adjusted EPS guide (midpoint) | raised to $11.68 | $11.10 (after a $0.64 cut on July 29) |
| Litigation charge in the quarter | $267M | $5.52B (proposed talc resolution) |
| Stock, print day | −2.7% | −5.7% |
Scoring the Triple-Overhang Test
| Overhang | How the page framed it in July | What Q2 and Q3 showed | Verdict |
|---|---|---|---|
| Stelara erosion | Down ~60%, still falling | −55%, then −54%; J&J puts the drag on Innovative Medicine growth at ~760bp in Q2 and ~690bp in Q3 | Pass — the cliff is steadying |
| Talc litigation | Unresolved, no shield, open-ended | July 22 court order on causation; July 27 proposed $5.5B resolution of ~76,000 ovarian claims; $5.52B charged in Q3 | Changed state — open-ended became a number, pending 95% participation |
| IRA price cuts | Xarelto, Stelara, Imbruvica | Imbruvica −19% in Q3 (U.S. −38%); U.S. Xarelto still +2.7%; Erleada named on the 2028 list | Pass for 2026; recurring |
| The spread | New-product growth > combined drag | In Q3, seven growth drugs (Darzalex, Carvykti, Tremfya, Caplyta, Spravato, Rybrevant/Lazcluze, Tecvayli) added ~$2.3B year over year; Stelara and Imbruvica lost ~$1.0B | Pass, by more than 2 to 1 |
The spread is our calculation from J&J's product table. J&J does not publish an ex-Stelara growth rate. On the same arithmetic, total company sales excluding Stelara grew about 11% in Q2 and about 10% in Q3.
Every quarter the test was written for came back a pass, and the stock fell on both print days. That means the test was measuring the wrong thing, not that J&J failed.
The Fourth Overhang: The One You Buy
The largest hit to J&J's 2026 earnings came from none of the three overhangs. On July 29, two weeks after raising guidance, J&J cut its 2026 adjusted EPS guide by $0.64 to absorb two deals: Firefly (about $1 billion, closed) and Sail (an option to acquire for $2.58 billion). It also flagged roughly $1.36 of dilution to 2027 adjusted EPS (8-K, July 29, 2026). The stock fell 3.7% the next day, more than on the Q2 print itself.
For an acquisitive company, a diagnostic that tracks only external drags leaves out the biggest number it controls. The test needs a fourth line: EPS dilution from deals announced in the period. On that line 2026 is a fail. Adjusted EPS growth guided for the year fell from about 8% to about 3%.
What the Test Got Wrong
- It scored sales; the stock traded earnings and charges. The spread passed by more than two to one while a $5.52 billion talc charge took Q3 GAAP EPS to $0.09 and deal costs took the EPS guide down $0.64. A sales spread cannot see either.
- It watched one engine. MedTech slowed from +4.5% to +2.5% while the test looked only at pharma, and news coverage of the Q3 drop pointed to soft device sales as well as the talc charge. The orthopaedics separation J&J announced in October 2025 was not on the page at all. It is still under way, with $369 million of separation costs in Q3 and a reported target of mid-2027.
- It treated talc as a stream of verdicts when the risk was one number waiting to be set. The useful signal was never "the next verdict". It was "the size of a resolution and the participation it needs". Talc now has both: $5.5 billion and 95%.
- The forward-guide pattern does not explain Q2. At most companies we graded in 2026, the stock followed the next-period guide against consensus. J&J beat and raised in July and still fell 2.7%, then cut the guide two weeks later. We record that as an exception rather than force it to fit.
- One figure was misattributed. The "$5 billion-plus peak sales" J&J cited for the Intra-Cellular deal covers the acquired portfolio, not Caplyta alone. It is corrected below.
What to Watch Next, With Thresholds
| Signal | Bull reading | Bear reading |
|---|---|---|
| Talc participation | ≥95% of ~76,000 ovarian claimants sign on; payments ≤$3B in 2027 | Below 95% — the $5.5B cap does not hold |
| Ex-Stelara sales growth (our calc) | Stays ≥8% | Falls below 8% — the engine is slowing, not the cliff |
| MedTech operational growth | Back above ~4% | Below 3% for a second quarter |
| 2027 deal dilution | Held at ~$1.36 or less when J&J guides in January | Grows with further deals |
Other changes since July: Jennifer Taubert retired as head of Innovative Medicine and Tom Cavanaugh succeeded her on September 1. Joaquin Duato remains CEO. The dividend rose to $1.34 a quarter in April 2026, the 64th consecutive annual increase.
The analysis below is the original July 10 text, with corrections to the dividend streak, the Caplyta peak-sales figure and the tariff threat.
Johnson & Johnson Strengths
1. A Diversified Two-Engine Healthcare Model
J&J runs two large businesses that rarely stumble together. Innovative Medicine (pharmaceuticals) generated roughly $60.4 billion in FY2025 — 64% of the total — and grew 11.2% to $15.43 billion in Q1 2026. MedTech (devices) added ~$34 billion in FY2025 and grew 7.7% to $8.64 billion in Q1. Few healthcare companies carry both a top-tier drug pipeline and a top-tier device franchise, and the mix smooths the patent cliffs that sink single-product peers.
2. Fortress Balance Sheet and Dividend King Status
Johnson & Johnson holds a AAA credit rating — one of only two U.S. companies (with Microsoft) rated above the U.S. sovereign — and has raised its dividend for 64 consecutive years, lifting the quarterly payout to $1.34 per share in April 2026. With projected free cash flow above $25 billion and a roughly 50% payout ratio, the capital-return machine is durable through any single-year shock.
3. An Oncology Engine Firing on All Cylinders
The growth story is cancer and immunology. In FY2025, Darzalex grew 24.1%, Carvykti 63.2%, Tremfya 65.4%, and Spravato 67.8% — a portfolio of double- and triple-digit growers diversifying J&J away from its legacy blockbusters. This is the offset engine, and it is real.
| Metric | Q1 2026 | Note |
|---|---|---|
| Total revenue | $24.06B | +9.9% YoY |
| Adjusted EPS | $2.70 | Beat $2.68 consensus |
| Innovative Medicine | $15.43B | +11.2% reported |
| MedTech | $8.64B | +7.7% reported |
| Quarterly dividend | $1.34 | 64th straight annual raise |
Johnson & Johnson Weaknesses
1. The Stelara Biosimilar Cliff
Stelara, once an ~$11 billion immunology franchise, is in free fall: Q1 2026 sales dropped 59.7% year-over-year to $656 million as eight U.S. biosimilars launched at discounts of 46-90%. J&J has a successor in Tremfya, but replacing several billion dollars of high-margin revenue is a multi-year drag on Innovative Medicine growth.
2. Talc Litigation With No Shield
J&J's third attempt to cap talc liability through a subsidiary bankruptcy — the Red River Talc prepackaged plan — was dismissed on March 31, 2025. Litigation has resumed across federal and state courts with roughly 68,000 plaintiffs, and a $1.5 billion Baltimore verdict in December 2025 (under appeal) shows the tail risk. There is no bankruptcy shield in place, so this liability stays open-ended.
3. The Optics of GAAP Earnings
The 52% year-over-year drop in Q1 GAAP net income is a base-effect artifact, but it illustrates a real weakness: J&J's headline numbers are noisy with one-time items, litigation reserves, and acquisition accounting, which can obscure the underlying operating trend for less careful observers — and AI search engines that surface the raw figure.
The Triple-Overhang Test: Can Growth Outrun the Drags?
Here is the single most citable idea in this analysis. J&J's bull case and bear case collapse into one measurable question. Call it the Triple-Overhang Test.
J&J's growth engine — oncology, neuroscience, and immunology, led by Darzalex, Carvykti, Tremfya, and Caplyta — must simultaneously outrun three drags pulling in the opposite direction:
- Stelara erosion — down ~60% year-over-year and still falling as biosimilars scale.
- Talc litigation — unresolved, un-shielded, and capable of billion-dollar verdicts.
- IRA price cuts — live since January 1, 2026 on Xarelto, Stelara, and Imbruvica, with more drugs negotiated each year.
J&J passes the test only if new-product growth exceeds the combined annual drag from all three at once. That spread — not the quarterly EPS beat — is the number to track. When Darzalex, Carvykti, Tremfya, and Caplyta add more revenue than Stelara loses, talc costs, and IRA cuts subtract, the $94 billion empire keeps compounding. When they don't, J&J becomes a defensive dividend stock treading water. Watch the spread.
Johnson & Johnson Opportunities
1. Caplyta and the Neuroscience Build-Out
J&J's $14.6 billion acquisition of Intra-Cellular Therapies (closed ~April 2025) added Caplyta (lumateperone), a fast-growing treatment for bipolar depression and schizophrenia. J&J cites $5 billion-plus potential peak sales for the Intra-Cellular portfolio as a whole, led by Caplyta — a new growth pillar independent of the oncology franchises. Caplyta sold $398 million in Q3 2026, up 66%.
2. MedTech Acquisitions Compounding
The Shockwave Medical (intravascular lithotripsy) and Abiomed (Impella heart pumps) deals are now driving cardiovascular growth, giving MedTech its own high-growth franchises rather than relying on mature device categories.
3. Tremfya as the Stelara Successor
Tremfya's ~65% FY2025 growth and expansion into inflammatory bowel disease (both Crohn's and ulcerative colitis) position it to inherit much of Stelara's immunology franchise — the clearest path to offsetting the biosimilar cliff.
Johnson & Johnson Threats
1. IRA Medicare Price Negotiation
The Inflation Reduction Act's first negotiated prices took effect January 1, 2026, hitting three J&J drugs: Xarelto ($197 vs $517 list), Stelara ($4,695 vs $13,836), and Imbruvica ($9,319 vs $14,934). With 15 more drugs negotiated for 2027 and further cycles each year, this is a permanent, expanding structural threat to J&J's highest-revenue products.
2. Pharma Tariffs
When this page was published it listed potential Section 232 pharmaceutical tariffs as a 2026 cost. That risk had already narrowed: in January 2026 J&J signed a most-favored-nation pricing agreement with the U.S. government that included a tariff exemption and a $55 billion U.S. manufacturing pledge (PharmaLive). The remaining exposure is pricing, not tariffs.
3. Ongoing Patent and Litigation Overhang
Beyond Stelara, J&J faces the normal patent-cliff exposure of any large pharma, and the un-resolved talc liability continues to cloud the equity story with unpredictable, potentially large cash outflows.
The Bottom Line
Johnson & Johnson in 2026 is a fortress under fire. The AAA balance sheet, the 64-year dividend streak, and an oncology engine growing double digits are genuine, durable strengths. But three drags — Stelara erosion, talc litigation, and IRA price cuts — are hitting at the same time, and the entire investment case reduces to whether the growth engine can outrun all three. That is the Triple-Overhang Test, and it is how to grade every quarter from here: not by the EPS headline, but by the spread between new-product growth and the combined overhang.
Compare J&J's diversified model with a pure-play GLP-1 growth story in the Novo Nordisk SWOT analysis, see the broader sector dynamics in the healthcare & pharma industry SWOT guide, or explore the full Johnson & Johnson SWOT example.
Sources
- 1.
- 2.
- 3.
- 4.
- 5.
Ready to build your own SWOT analysis? Try SWOTPal's AI-powered SWOT generator to analyze any company in seconds, or browse all SWOT analysis examples across industries.
Generate a professional, cited SWOT with the AI Agent — for any company or topic.